Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0
1

Year Published

2016
2016
2022
2022

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(5 citation statements)
references
References 17 publications
0
4
0
1
Order By: Relevance
“…We emphasize that urinary RT-PCR-based PSMA tests merit further investigation, but we believe that PSMA has the potential to be a robust biomarker. Recently, a number of studies confirmed that PSMA serves as a good target for molecular imaging in PET examinations [ 21 , 22 ] and potential targets in the treatment of metastatic castration-resistant prostate cancer (mCRPC) [ 23 ]. However, some limitations of this study must be acknowledged.…”
Section: Discussionmentioning
confidence: 99%
“…We emphasize that urinary RT-PCR-based PSMA tests merit further investigation, but we believe that PSMA has the potential to be a robust biomarker. Recently, a number of studies confirmed that PSMA serves as a good target for molecular imaging in PET examinations [ 21 , 22 ] and potential targets in the treatment of metastatic castration-resistant prostate cancer (mCRPC) [ 23 ]. However, some limitations of this study must be acknowledged.…”
Section: Discussionmentioning
confidence: 99%
“…The construction of PSMA-1 was, according to the schematic illustration in Scheme 1 , based on previously reported research with modification [ 33 ]. Carbonyl protected L -glutamine ( 1 ) and L -lysine ( 3 ) were key intermediates.…”
Section: Resultsmentioning
confidence: 99%
“…Copper (II) ion was employed to induce chelation of the α amino group and the carboxyl group, which allowed the free ε amino group protection first. Fmoc group was much more convenient to be deprotected (with diethyl amine) compared to Boc protection (with Pt/C+H 2 ) [ 23 , 33 ]. Meanwhile, we developed the Boc deprotection of α amino group and protection of α carbonyl group in signal one step with good yield (70%).…”
Section: Resultsmentioning
confidence: 99%
“…To date, a variety of urea-based PSMA inhibitors have been developed and labeled with different SPECT ( 99m Tc, 111 In), PET ( 68 Ga, 64 Cu), and therapeutic ( 177 Lu) radiometals using several chelators and showed great promise not only preclinicaly but also in the clinical assessment. Apart from the radiometals to be used as the cytotoxic units, a considerable amount of urea-based PSMA inhibitors labeled with 11 C, 125 I, 124 I, 131 I and 18 F, have also been reported [ 19 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 ]. These radiotracers were also able to successfully image PSMA-expressing xenografted mice, but since this is beyond the focus of this review no further information will be given here with regard to this topic.…”
Section: Urea-based Psma Inhibitorsmentioning
confidence: 99%